FOURIER-OLE trial finds that long-term use of evolocumab further reduced cardiovascular events

Retrieved on: 2022-08-30 14:04:49

Tags for this article:

Click the tags to see associated articles and topics

FOURIER-OLE trial finds that long-term use of evolocumab further reduced cardiovascular events. View article details on hiswai:

Excerpt

... Novartis, AstraZeneca, Janssen, Intarcia and GlaxoSmithKline and consulting fees from Amgen, Novartis, AstraZeneca and Janssen.

Article found on: www.eurekalert.org